1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK
  4. CDK19 Isoform

CDK19

 

CDK19 Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-111388A
    SEL120-34A monohydrochloride
    Inhibitor 98.69%
    SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8.
  • HY-19984
    CCT-251921
    Inhibitor 98.86%
    CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM.
  • HY-126675A
    AS2863619
    Inhibitor ≥98.0%
    AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases.
  • HY-15681
    Senexin A
    Inhibitor 99.85%
    Senexin A is a CDK8 inhibitor with an IC50 of 280 nM.
  • HY-122586
    BRD6989
    Inhibitor 99.85%
    BRD6989, an analog of the natural product cortistatin A (dCA), inhibits CDK8 and upregulates IL-10.
  • HY-143889
    Senexin C
    Inhibitor
    Senexin C is a selective and orally active CDK8/19 inhibitor.
  • HY-126675
    AS2863619 free base
    Inhibitor ≥98.0%
    AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases.
  • HY-111388B
    SEL120-34A HCl
    Inhibitor 99.98%
    SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
  • HY-139875
    JH-XVI-178
    Inhibitor 98.16%
    JH-XVI-178 is a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties.
  • HY-111388
    SEL120-34A
    Inhibitor
    SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
  • HY-111427
    CDK8/19-IN-1
    Inhibitor
    CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively.